503 First results of diflomotecan, a new topoisomerase 1 inhibitor, as oral soft-gel capsules in a phase I dose escalation study in patients with advanced malignant solid tumours

T.Lesimple; P.Fumoleau; A.Lortholary; J.Egreteau; M.Campone; P.Soulie; B.Le Mosquet

首页> 外文期刊>European Journal of Cancer Supplements >503 First results of diflomotecan, a new topoisomerase 1 inhibitor, as oral soft-gel capsules in a phase I dose escalation study in patients with advanced malignant solid tumours

【24h】

503 First results of diflomotecan, a new topoisomerase 1 inhibitor, as oral soft-gel capsules in a phase I dose escalation study in patients with advanced malignant solid tumours

机译：503一种新的拓扑异构酶1抑制剂地氟米特康作为口服软胶囊的第一阶段结果在晚期恶性实体瘤患者的I期剂量递增研究中

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2004年第8期|共2页
作者
T.Lesimple; P.Fumoleau; A.Lortholary; J.Egreteau; M.Campone; P.Soulie; B.Le Mosquet;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours [J] . Kyaw L. Aung, Anthony B. El-Khoueiry, Karen Gelmon, Investigational new drugs. . 2018,第6期

机译：一种多臂期I剂量升级高级实体肿瘤患者口腔腹部抑制剂BMS-986115的研究
2. A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours. [J] . Thomas Anne L, Molife L Rhoda, Ahmed Samreen, Cancer chemotherapy and pharmacology. . 2009,第2期

机译：口服多靶标生长抑制剂（MTGI）ZK 304709在晚期实体瘤患者中的药代动力学和耐受性的I期剂量递增研究。
3. A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours [J] . Edwina N. Scott, Anne L. Thomas, L. Rhoda Molife, Cancer Chemotherapy and Pharmacology . 2009,第2期

机译：口服多靶点生长抑制剂（MTGI ™）ZK 304709在晚期实体瘤患者中的药代动力学和耐受性的I期剂量递增研究
4. A Phase I, Double-Blind, Randomized, Dose Escalating Crossover Study ofan Oral Formulation of Human Growth Hormone in Healthy Male Volunteers [C] . Steven M. Dinh, Puchun Liu, Ehud Arbit, Controlled Release Society annual meeting . 2004

机译：健康男性志愿者中人类生长激素口服制剂的I期，双盲，随机，剂量递增交叉研究
5. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
6. A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours [O] . Alison M. Schram, Leena Gandhi, Monica M. Mita, 2018

机译：晚期实体瘤患者口服MEK抑制剂pimasertib和PI3K / MTOR抑制剂voxtalisib的Ib期剂量递增和扩展研究
7. A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours [O] . Alison M. Schram, Leena Gandhi, Monica M. Mita, 2018

机译：患有先进实体肿瘤的患者口服梅克抑制剂Pimasertib和PI3K / MTOR抑制剂Voxtalisib的IB剂量 - 升级和扩展研究

503 First results of diflomotecan, a new topoisomerase 1 inhibitor, as oral soft-gel capsules in a phase I dose escalation study in patients with advanced malignant solid tumours

著录项

相似文献

相关主题

期刊订阅